2016
Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner
Mundra J, Jian J, Bhagat P, Liu C. Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner. Scientific Reports 2016, 6: 21115. PMID: 26892362, PMCID: PMC4759551, DOI: 10.1038/srep21115.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesChemokine CXCL10Chemokine CXCL9Cluster AnalysisDermatitis, ContactGene Expression ProfilingGene Expression RegulationIntercellular Signaling Peptides and ProteinsMacrophagesMiceMice, KnockoutProgranulinsReceptors, Tumor Necrosis Factor, Type IRecombinant ProteinsConceptsWild-type B6 micePGRN KO miceRecombinant PGRN proteinTNFR1-dependent mannerSeverity of inflammationInflammatory bowel diseaseAnti-inflammatory functionalityCXCL9 expressionTreg populationGene array analysisBowel diseaseDermatitis modelRheumatoid arthritisChemokine expressionChemokines CXCL9Autoimmune diseasesB6 micePGRN functionCXCL10 expressionKO miceT cellsPleiotrophic growth factorsImmune systemProgranulinNull mice
2014
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism
Zanin-Zhorov A, Weiss J, Nyuydzefe M, Chen W, Scher J, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky M, Tonra J, Hippen K, Dustin M, Blazar B, Liu C, Waksal S. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 16814-16819. PMID: 25385601, PMCID: PMC4250132, DOI: 10.1073/pnas.1414189111.Peer-Reviewed Original ResearchConceptsT cellsIL-17IL-21Forkhead box P3 (Foxp3) expressionRegulatory T cell subsetsPhase 1 clinical trialCollagen-induced arthritisIL-17 secretionRegulatory T cellsRheumatoid arthritis patientsTreatment of autoimmunityBox P3 expressionT cell subsetsDevelopment of autoimmunityROCK2 inhibitorIFN regulatory factor 4Healthy human subjectsT cell receptor stimulationIL-21 promoterSTAT3-dependent mechanismRegulatory factor 4Human T cellsArthritis patientsSiRNA-mediated inhibitionProinflammatory cytokines